Alzheimer’s disease, the most common form of dementia, is a progressive neurological illness that impairs thinking and the independence of millions of people worldwide.¹ Today, more than 55 million people live with dementia worldwide, and Alzheimer’s disease may contribute to 60-70% of cases.²

Alzheimer’s disease is usually diagnosed in people 65 years and older, but it starts earlier, with subtle neurological changes occurring years or even decades before symptoms appear.¹ Many people are experiencing the early, often unrecognised signs of mild cognitive impairment.³

Driven by our commitment to people living with Alzheimer’s disease and their carers, along with our strong business foundation, Biogen remains dedicated to furthering research and investigating treatment options, aiming to help address the unmet needs in this devastating condition, with an emphasis on early-stage disease.

We understand how incredibly challenging it is to treat this complex condition, which is why we will never stop innovating for those living with the condition, their families and service providers in the Alzheimer’s community. We are currently conducting clinical trials to evaluate the efficacy and safety of investigational therapies in our pipeline, including Alzheimer’s disease.